Online tool as a treatment decision aid

Study title

Navigate: Randomised Control Trial of an online treatment decision aid for men with low-risk prostate cancer and their partners.

Lead investigator

Prof Penelope Schofield, Peter MacCallum Cancer Centre.

Summary of project

Men recently diagnosed with low risk prostate cancer are needed to take part in a study assessing a new online tool designed to help navigate their treatment.

The Navigate clinical trial is recruiting men diagnosed with low-risk or localised prostate cancer within the last three months.

Low-risk prostate cancer often grows very slowly or not at all, yet men faced with this diagnosis report more difficulty making a treatment decision than any other cancer clinical group. This is largely due to the variety of management options including Active Surveillance (close monitoring) versus active treatment such as radiotherapy or surgery

The Navigate website has been developed by a team of experts and men with first-hand experience of prostate cancer. Men and their partners can access the decision-making exercise to help them arrive at a treatment decision. Included are over 40 videos of men, partners, oncologists, urologists and specialist prostate nurses to provide a range of perspectives and personal experiences.

Like the flip of a coin, some participants will be given access to the Navigate tool while others will be assigned another prostate cancer website. Both sites provide up-to-date and evidence-based information about low-risk prostate cancer and the different treatment options available.

Participants will also be asked to complete four online questionnaires over a six-month period. Each questionnaire will take about 15-20 minutes to complete (1-2 hours in total).

This Swinburne University funded project is recruiting both online and from Peter MacCallum Cancer Centre, Cabrini Health, Austin Health, Alfred Health and Western Health.

Men can register their interest to participate at www.navigateprostate.com.au.

Partners are also welcome to participate.

Ethics approval

Ethics approval has been granted by the Peter MacCallum Cancer Centre Human Research Ethics Committee.

Who is this study for?

You may be eligible for this study if you:

  • Have been diagnosed with low-risk prostate cancer within the last three months
  • Are still deciding on your treatment options and one option includes Active Surveillance (to be confirmed with your doctor)
  • You have access the internet and are able to meet the study requirements

If you are interested in this study, please contact:

Navigate Research Team
(03) 8559 7453 navigate@petermac.org or go to www.navigateprostate.com.au

September 24th, 2018|